MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, IKT had $82,729,629 increase in cash & cash equivalents over the period. -$27,799,863 in free cash flow.

Cash Flow Overview

Change in Cash
$82,729,629
Free Cash flow
-$27,799,863
Unit: Dollar
Positive Cash Flow Breakdown
    • Proceeds from issuance of common...
    • Maturities of investments - mark...
    • Stock-based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Purchases of investments - marke...
    • Prepaid research and development
    • Others

Cash Flow
2025-12-31
Net loss
-48,259,189
Depreciation
60,499
Stock-based compensation expense
15,309,924
Write-off of in-process research and development
7,357,294
Change in fair value contingent consideration
1,373,942
Non-cash accretion on marketable securities
936,975
Operating lease right of use assets
101,437
Prepaid expenses and other assets
-532,732
Prepaid research and development
1,920,685
Other assets
95,121
Accounts payable
146,827
Operating lease liabilities
110,517
Accrued expenses and other current liabilities
1,401,252
Net cash used in operating activities
-27,786,464
Purchases of equipment and improvements
13,399
Purchases of investments - marketable securities
39,094,847
Maturities of investments - marketable securities
41,600,000
Acquired in-process research and development
438,624
Net cash provided by (used in) investing activities
2,053,130
Proceeds from issuance of common stock, pre-funded warrants and warrants, net of issuance costs
107,617,495
Issuance of common stock from exercise of stock options
845,468
Net cash provided by financing activities
108,462,963
Net increase in cash and cash equivalents
82,729,629
Cash and cash equivalents at beginning of year
56,490,579
Cash and cash equivalents at end of year
139,220,208
Unit: Dollar.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock,...$107,617,495 Issuance of common stockfrom exercise of...$845,468 Maturities of investments -marketable securities$41,600,000 Net cash provided byfinancing activities$108,462,963 Net cash provided by(used in) investing...$2,053,130 Canceled cashflow$39,546,870 Net increase in cashand cash...$82,729,629 Canceled cashflow$27,786,464 Stock-based compensationexpense$15,309,924 Write-off of in-processresearch and development$7,357,294 Accrued expenses andother current...$1,401,252 Prepaid expenses andother assets-$532,732 Accounts payable$146,827 Operating lease right ofuse assets$101,437 Depreciation$60,499 Purchases of investments -marketable securities$39,094,847 Acquired in-processresearch and development$438,624 Purchases of equipment andimprovements$13,399 Net cash used inoperating activities-$27,786,464 Canceled cashflow$24,909,965 Net loss-$48,259,189 Prepaid research anddevelopment$1,920,685 Change in fair valuecontingent consideration$1,373,942 Non-cash accretion onmarketable securities$936,975 Operating leaseliabilities$110,517 Other assets$95,121

Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics, Inc. (IKT)